Cadila gets US drug regulator’s warning over quality issues

The company says it will action but stock market not convinced

GN Bureau | December 31, 2015



Cadila Healthcare Ltd said it received a warning from US health regulators for violating manufacturing standards at two production sites in India. The letter from the US Food and Drug Administration cites issues at Cadila's plants in Moraiya drug production site and another in Ahmedabad city where it makes drug ingredients.

Strangely, the company says that there are no products in the US market which use API of Zyfine facility.

On Thursday, Cadila said in a statement that it was "committed to resolve all the issues and revamp our quality systems and processes as the top most priority."

“The company has received a warning letter issued by the US FDA relating to its Moraiya formulation facility and Ahmedabad API facility (Zyfine),” Cadila Healthcare said in a regulatory filing.

Cadila said none of its products being sold in the United States used any raw materials made at the Ahmedabad plant.

"The company said it will respond to US FDA to address the observations within the statutory time permitted in the letter. The company is working hard to ensure that the commitments made to the US FDA are fully completed. The company will continue to take all necessary steps to ensure that the US FDA is fully satisfied with our remediation of the above facilities," it added.

Despite these clarifications, its shares fell by 17%. This is its biggest single-day percentage fall.

Cadila has already gained site transfer approvals for 4 of its existing products. Also, its new SEZ formulations facility (oral Oncology, oral solids) received the Establishment Inspection Report (EIR) from the USFDA.

The warning for Moraiya comes more than a year after the FDA inspected the plant in 2014, and issued a report highlighting a series of problems. Cadila said in October its work to fix the issues was complete.

Comments

 

Other News

Does AAP continue to suffer from political immaturity?

Does AAP continue to suffer from political immaturity?

Pride and Kshatriya prejudice

There`s a popular folktale shaped by the tongues of the bards and storytellers of Rajasthan about the folly of Rajputs. A Rajput crossing a dense, dark jungle falls into a dry, abandoned well. He is trapped for hours till a passing youth throws him a rope and pulls him up. Nea

Everything you need to know about Justin Trudeau’s India trip

The Canadian PM has received an official reception by the prime minister of India Narendra Modi on Friday at the Rashtrapati Bhavan. The two are expected to talk some serious business at the bilateral meeting, and are expected to focus on trade, defence, civil nuclear cooperation, space, tackling climate c

Key facts in Vikram Kothari`s round-tripping case

Have you used Rotomac pen? The brand is owned by a Kanpur-based Kothari family, which owns Rotomac Global, now under CBI and ED scanner for round-tripping. Rotomac Global is run by Vikram Kothari, who is also the managing director with the firm. A key allegation against Kothari is that he o

Corruption perception: What India needs to do

India is faring worse and worse on Transparency International’s ‘Corruption Perception Index’: the latest for 2017 shows India ranking a poor 81 (placed between Ghana and Morocco) and the same 40 points out of 100 as the previous year. In 2015 and 2014, the number stood at 38 and

In the age of RTI, black money info goes inside a black hole

During his reply on the Motion of Thanks to the Address of the President of India, in the Lok Sabha on February 7, prime minister Narendra Modi compared his government`s efforts to curb corruption and flush out black money to Swachh Bharat Abhiyan – the nationwide mission launched to clean up cities,

Current Issue

Current Issue

Video

CM Nitish’s convoy attacked in Buxar

Opinion

Facebook    Twitter    Google Plus    Linkedin    Subscribe Newsletter

Twitter